ClinicalTrials.gg
RecruitingNCT06173427Head-TraumaUpdated Dec 15, 2023

Monitoring of Intracranial Hemorrhage in Non-severe Head Trauma Patients Hospitalized in the UHCD

An observational study in Head Trauma, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Craniocerebral Trauma with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Craniocerebral Trauma · France.

Planned enrollment
10th of 21
180 · median 130
Started
2019
with 2 others
Observational
21 of 36
4 open now
Registered
26th of 36
by date
Lead sponsor
3 of 36
University Hospital, Strasbourg, France

Among the 36 studies in Craniocerebral Trauma with a site in France, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2019, is one of 21 observational ones, and was the 26th registered.

Craniocerebral Trauma

253 studies on the registry are indexed under Craniocerebral Trauma; 45 are open to participants now.

Browse Craniocerebral Trauma studies →

Open to participants now

6 of the 36 studies in Craniocerebral Trauma with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 25 Craniocerebral Trauma studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Craniocerebral Trauma with a site in France, or all of them as a file.
02

Study summary

The non-neurosurgical management of post-traumatic cerebral hemorrhagic lesions is currently poorly codified. It consists of neurological monitoring for 24 to 48 hours, and the performance of an almost systematic brain scan. Anti-aggregation and anticoagulation treatments are stopped for 14 to 28 days and should be resumed according to the risk-benefit ratio and the advice of the patient's treating physicians and cardiologists.

If the bleeding lesions do not progress, the patients are allowed to return home. If the lesions progress, the patients remain hospitalized for further monitoring, a new brain scan and neurosurgical advice.

This study seeks to show that the performance of systematic brain imaging in the absence of clinical deterioration of patients admitted to the UHCD for post-traumatic intracranial hemorrhage could be avoided, and thus to administer an unnecessary dose of irradiation to the patients, and would also have a significant financial stake.

Several recent studies have shown that there is no need to perform a follow-up brain scan in the absence of neurological deterioration, even in anticoagulated patients or those on antiplatelet drugs. Despite the growing number of articles, no recommendation or consensus has been proposed.

03

Conditions studied

  • Head Trauma

Keywords

  • Head Trauma
  • Intracranial hemorrhage
  • Cerebral hemorrhagic lesions
  • Neurological monitoring
  • Brain scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patient (≥18 years old) admitted to Emergency department of the Strasbourg University Hospital during the year 2017 (from 01/01/2017 to 31/12/2017)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥18 years old)
  • Admitted to Emergency department of the Strasbourg University Hospital during the year 2017 (from 01/01/2017 to 31/12/2017)
  • Patient having given his consent to the reuse of his data for the purpose of this research
  • Hospitalized at the University Hospital for monitoring of a post-traumatic intracranial hemorrhage

Exclusion criteria

Exclusion criteria:

  • Patient having expressed opposition to participate in the study
  • Non-isolated cranial trauma (MVA, fall greater than 6 meters ..)
  • Subject under court protection
  • Subject under guardianship or curatorship
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
180 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retrospective description of clinical evolution of post-traumatic intracerebral hemorrhages

    Time frame: Through study completion, an average of 4 months

07

Study locations

1 of 1 sites recruiting
  • Service d'accueil des urgences - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Florent BAICRY, MD · Contactflorent.baicry@chru-strasbourg.fr · 33 3 88 12 86 82
    • Florent BAICRY, MD · Principal investigator
    • Valentin DE CARLO, MD · Sub investigator
    • Pascal BILBAULT, MD, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2019 (actual). Primary completion is estimated for Dec 2023, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Dec 15, 2023
StartActual
Nov 1, 2019
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06173427
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Nov 1, 2019
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Dec 15, 2023

Study contacts

Florent BAICRY, MD
Contact
florent.baicry@chru-strasbourg.fr
33 3 88 12 86 82

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion